Law360, New York (September 09, 2011, 8:53 PM ET) -- Flamel Technologies SA hit Anchen Pharmaceuticals Inc. with a patent suit Friday, alleging the drug manufacturer infringed a patent for Flamel's heart failure drug Coreg when it submitted a bid to produce a generic version.
According to the complaint filed in Maryland federal court, Flamel, a drugmaker based in France, was informed in July that Anchen had asked the U.S. Food and Drug Administration for approval to develop a generic version of a 40-milliliter carvedilol phosphate capsule, using the active ingredient in Flamel's Coreg.
The patent-in-suit...
Flamel Seeks To Block Generic Coreg
To view the full article, take a free trial now.
